Sarepta Therapeutics (NASDAQ:SRPT) has hired a lobbying firm with close ties to the Trump administration as regulatory ...

Sarepta Therapeutics (NASDAQ:SRPT) resumed its recent sell-off on Thursday after Endpoints News reported that the FDA would require the company to conduct new studies to address safety concerns and ...

Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most undervalued stocks to buy and hold for 3 years. On July 22, BMO ...

Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its experimental gene therapies. The company confirmed that a 51-year-old, non ...

Deep-pocketed investors have adopted a bullish approach towards Sarepta Therapeutics (NASDAQ:SRPT), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Sarepta Therapeutics (NASDAQ:SRPT) shares dropped sharply premarket on Monday before paring losses as Barclays revised its ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Bank of America downgraded Sarepta Therapeutics (NASDAQ:SRPT) to Underperform from Neutral on Wednesday, becoming the latest brokerage to issue a bearish view on the company, citing safety concerns ...

July 17, 2025 — 08:21 am EDT Written by Quiver ForecastTracker for Quiver Quantitative -> ...

Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their ...

Roche (OTCQX:RHHBY) has decided to pause overseas shipments of Elevidys gene therapy developed by Sarepta Therapeutics (NASDAQ:SRPT) following safety concerns raised in the U.S., Reuters reported, ...